Inmune Bio originally focused on using a dominant-negative TNF protein (DN-TNF) for cancer immunotherapy, which failed to show efficacy. Now, they’ve pivoted to neurology—repurposing the same molecule (XPro1595) for Alzheimer’s. The science behind targeting neuroinflammation is still early, and their approach lacks robust clinical validation.
They're in Phase 2, but data is sparse, the trial is small, and biomarkers—not clinical outcomes—are the main readout. With limited cash (~$20M as of last filing) and a high burn rate, they’ll likely need to raise before any real catalyst hits. High risk of dilution, weak scientific precedent, and a recycled failed asset = recipe for another disappointment.
Conclusion: This Alzheimer’s pivot feels like a Hail Mary. Market’s giving them credit for a turnaround that probably won’t work again ❌
They're in Phase 2, but data is sparse, the trial is small, and biomarkers—not clinical outcomes—are the main readout. With limited cash (~$20M as of last filing) and a high burn rate, they’ll likely need to raise before any real catalyst hits. High risk of dilution, weak scientific precedent, and a recycled failed asset = recipe for another disappointment.
Conclusion: This Alzheimer’s pivot feels like a Hail Mary. Market’s giving them credit for a turnaround that probably won’t work again ❌
액티브 트레이드
Always happy to create generational wealth for my followers
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.